Contraindications for using Bosutinib

Bosutinib/Bosutinib (Bosutinib) is a targeted therapy drug mainly used to treat chronic myeloid leukemia (CML). As a tyrosine kinase inhibitor, bosutinib prevents the proliferation and spread of cancer cells by inhibiting Bcr-Abl tyrosine kinase activity. However, like all drugs, bosutinib also has some contraindications and precautions. Ensuring safe use of the drug is the key to successful treatment.

First, the use of bosutinib is strictly contraindicated in patients with known hypersensitivity to bosutinib or its components. Such patients may have allergic reactions to drug ingredients, such as rash, shortness of breath, throat swelling, etc. In severe cases, anaphylactic shock may occur. Therefore, before using bosutinib, patients must inform their doctor if they have any history of allergies, especially to bosutinib or similar drug ingredients. Doctors usually conduct allergen screening and decide whether the drug is suitable for the patient's specific situation.

Second, bosutinib needs to be used with caution in patients with hepatic impairment. Studies have shown that bosutinib may cause liver impairment, especially in patients with impaired hepatic function. Therefore, patients with hepatic insufficiency should pay special attention to monitoring liver enzyme levels when using bosutinib, and adjust drug dosage or suspend treatment if necessary. If the patient has severely impaired liver function, it is generally recommended to avoid bosutinib or to pursue other treatment alternatives.

In addition, the use of bosutinib also requires caution about its impact on the cardiovascular system. Bosutinib may cause cardiovascular adverse reactions such as electrocardiogram abnormalities and QT interval prolongation, especially in patients with a history of cardiovascular disease. Therefore, when such patients are taking bosutinib, they should undergo regular electrocardiogram examinations to ensure that there are no adverse reactions such as QT prolongation. If the QT interval is found to be significantly prolonged, the treatment plan should be adjusted promptly or the drug should be discontinued.

Keyword tags: Bosutinib,Bosutinib, contraindications, allergic reactions, hepatic insufficiency, cardiovascular disease, QT interval prolongation, drug interactions

Reference materials:https://www.drugs.com/mtm/bosutinib.html